SCHEMBL3590475

SCHEMBL3590475

[CH](N1CCCCC1)N1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.46
CHKA P35790 1/20 0.46
KDM4E B2RXH2 1/20 0.46
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HRH1 P35367 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA9 Q16790 1/20 0.32
SIGMAR1 Q99720 2/20 0.31
HTR3E A5X5Y0 1/20 0.31
HTR3B O95264 1/20 0.31
ADRB1 P08588 1/20 0.31
HTR3A P46098 1/20 0.31
HTR3D Q70Z44 1/20 0.31
HTR3C Q8WXA8 1/20 0.31
HTR6 P50406 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28203883 0.88 ADRB1 (0.36) CA2CHKAKDM4ESMN1; SMN2HRH1
SCHEMBL2254566 0.82 CA1 (0.35) CA2SMN1; SMN2ALDH1A1CA1TP53
SCHEMBL28394201 0.82 CA1 (0.35) CA2SMN1; SMN2ALDH1A1CA1TP53
SCHEMBL2251329 0.82 CA1 (0.35) CA2SMN1; SMN2ALDH1A1CA1TP53
SCHEMBL4717441 0.82 CA1 (0.35) CA2SMN1; SMN2ALDH1A1CA1TP53
Cyclopropane SCHEMBL28399372 0.78 CA2 (0.41) CA2CHKAKDM4EUSP2SMN1; SMN2
Cyclopropane SCHEMBL28392647 0.76 CA2 (0.39) CA2CHKAKDM4EUSP2SMN1; SMN2
SCHEMBL519409 0.74 ALDH1A1 (0.38) CA2CHKAKDM4EUSP2SMN1; SMN2
SCHEMBL930605 0.71
SCHEMBL12671511 0.71 CA2 (0.35) CA2CHKAKDM4ECA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107001358-A Adjust the new pyridine hepyramine compound of istone lysine demethylase (KDM) catalytic activity 东亚ST株式会社 2017-08-01 CN claimed
EP-2118048-A2 MALE CONTRACEPTIVE King's College London (GB) 2009-11-18 EP claimed
WO-2008087421-A2 MALE CONTRACEPTIVE KING'S COLLEGE LONDON (GB) 2008-07-24 WO claimed
CN-104870422-B Amine derivative or its salt 富士胶片富山化学株式会社 2019-03-15 CN disclosed
CN-106279138-B Aromatic heterocyclic derivatives and its application in drug 广东东阳光药业有限公司 2019-03-01 CN disclosed
CN-109311868-A Compound for treating cancer and inflammatory disease 尚医治疗有限责任公司 2019-02-05 CN disclosed
CN-105399698-B Aromatic heterocyclic derivatives and its application in drug 广东东阳光药业有限公司 2018-08-10 CN disclosed
CN-107428749-A The substituted ylamine compounds of imidazo [1,2 α] pyridine 2 and its pharmaceutical composition and application method 南京泽宁医药研发有限公司 2017-12-01 CN disclosed
CN-106279138-A Heteroaromatic analog derivative and the application in medicine thereof 广东东阳光药业有限公司 2017-01-04 CN disclosed
EP-2118048-B1 MALE CONTRACEPTIVE AMOBI NNAEMEKA IKECHUKWU (GB) 2016-11-23 EP disclosed
US-8927579-B2 Male contraceptive Amobi, Nnaemkea Ikechukwu (GB) 2015-01-06 US disclosed
US-8778968-B2 2014-07-15 US disclosed
US-20100029624-A1 Male Contraceptive KING'S COLLEGE LONDON (GB) 2010-02-04 US disclosed
EP-2118048-A2 MALE CONTRACEPTIVE King's College London (GB) 2009-11-18 EP disclosed
WO-2008087421-A2 MALE CONTRACEPTIVE KING'S COLLEGE LONDON (GB) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029624-A1 Male Contraceptive NR5A1, AR, CYP19A1 CA2 4635/4885CHKA 3698/4885KDM4E 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.